#contributionPrecise evidence for sustained weight reduction
At 80 weeks, retatrutide 12 mg produced an estimated 18.8% weight reduction versus 5.1% with placebo, with a placebo-adjusted difference of −13.8 percentage points. HbA1c also improved across all retatrutide doses.
↳ Results; Table 2
#methodological rigourRandomised design with explicit analytical safeguards
Central stratified randomisation and double masking are paired with randomised-population analyses, two prespecified estimands and multiplicity control for primary and key secondary endpoints.
↳ Methods, Randomisation and masking and Statistical analysis; Tables 1–2
#methodological rigourSystematic collection and reporting of harms
Safety reporting includes discontinuations, deaths and prespecified events of interest, with independent adjudication of cardiovascular, pancreatic and neurological events. Gastrointestinal events, dysesthesia and hypotension are explicitly reported.
↳ Methods, Outcomes; Results, safety; Table 3